These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Mahdi AJ, Obaji SG, Collins PW. Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016 [Abstract] [Full Text] [Related]
9. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J. Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111 [Abstract] [Full Text] [Related]
10. Prophylaxis for severe haemophilia: clinical and economical issues. Fischer K, Van Den Berg M. Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671 [Abstract] [Full Text] [Related]
12. The overall effectiveness of prophylaxis in severe haemophilia. Panicker J, Warrier I, Thomas R, Lusher JM. Haemophilia; 2003 May; 9(3):272-8. PubMed ID: 12694517 [Abstract] [Full Text] [Related]
13. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Stobart K, Iorio A, Wu JK. Cochrane Database Syst Rev; 2005 Apr 18; (2):CD003429. PubMed ID: 15846666 [Abstract] [Full Text] [Related]
14. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Stobart K, Iorio A, Wu JK. Cochrane Database Syst Rev; 2006 Apr 19; (2):CD003429. PubMed ID: 16625581 [Abstract] [Full Text] [Related]